A password will be e-mailed to you.

New Vaccine Technology Shows Promise as a Tool to Combat the Opioid Crisis

Summary: A new vaccine blocks the effects of heroin by preventing the drug from crossing the blood-brain barrier. Researchers believe the vaccine could be helpful in curbing the opioid epidemic.

Source: U.S. Military HIV Research Program.

Researchers with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) report that an experimental heroin vaccine induced antibodies that prevented the drug from crossing the blood-brain barrier in mice and rats. The vaccine was co-developed at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, which funded the preclinical research.

“By eliciting antibodies that bind with heroin in the blood, the vaccine aims to block the euphoria and addictive effects,” said Dr. Gary Matyas, Chief of Adjuvants and Formulations for the U.S. Military Research Program (MHRP), WRAIR. “We hope to give people a window so they can overcome their addiction.”

The study, published in the Journal of Medicinal Chemistry, showed that the vaccine produced antibodies against other commonly misused opioids, including hydrocodone, oxycodone, hydromorphone, oxymorphone and codeine. The vaccine appeared to dampen the impact of heroin at a high-dose, which might indicate a potential to prevent overdose.

In clinical settings, it is essential that the antibodies induced by a heroin or opioid vaccine do not cross-react with the therapies for opioid misuse, such as methadone, buprenorphine and naltrexone. Researchers found that the antibodies did not react with these compounds and, more importantly, the antibodies induced by the vaccine did not cross-react with naloxone, which is used as the overdose rescue treatment to reverse respiratory depression due to heroin and other opioid overdose.

Although the use of opioids for pain management in people suffering from addiction is of concern, researchers found that methadone, tramadol, fentanyl, sufentanil, nalbuphine and buprenorphine did not bind to the antibodies, indicating that they could be used if acute pain treatment is required for emergency use in vaccinated patients. Researchers also found that there was no binding to the non-narcotic pain relievers like aspirin, ibuprofen and acetaminophen, so these would likely remain effective.

Image shows vaccine vials.

Dr. Gary Matyas’ lab at the Walter Reed Army Institute of Research. NeuroscienceNews.com image is credited to MHRP.

The misuse of opioids, which include heroin and fentanyl, is a growing problem in the U.S. According to the CDC, 91 Americans die every day from an opioid overdose. Most pharmacological treatments for opioid misuse involve opioid management therapy (OMT), but treatment access is an issue. In addition, adherence varies greatly and relapse rates can be high. To end the opioid overdose crisis, many different types of treatments and medications will be needed to meet the needs of individuals addicted to these drugs.

“Although we are still in the early phase, this study suggests that vaccination can be used together with standard therapies to prevent the withdrawal and craving symptoms associated with opioid withdrawal,” said Matyas.

WRAIR researchers leveraged their expertise in vaccine development and novel adjuvants research to develop this experimental heroin vaccine with their partners at NIDA. The vaccine includes a potent adjuvant to stimulate the immune system called the Army Liposome Formulation (ALF), which was also developed by researchers at WRAIR. The vaccine was developed jointly with intramural scientists at the Drug Design and Synthesis Section (Dr. Kenner C. Rice, Chief), Molecular Targets and Medications Discovery Branch, NIDA.

About this neuroscience research article

Funding: This work was supported by the NIH Intramural Research Programs of the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, and through a Cooperative Agreement Award (no. W81XWH-07-2-067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine and the U.S. Army Medical Research and Materiel Command (MRMC). The work was partially supported by an Avant Garde award from NIDA (NIH grant no. 1DP1DA034787-01). The X-ray crystallographic work was supported by NIDA through an Interagency Agreement #Y1-DA1101 with the Naval Research Laboratory (NRL).

Source: Lisa Reilly – U.S. Military HIV Research Program
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is credited to U.S. Military HIV Research Program.
Original Research: Abstract for “A Stable Heroin Analog That Can Serve as a Vaccine Hapten to Induce Antibodies that Block the Effects of Heroin and its Metabolites in Rodents and that Cross-React Immunologically with Related Drugs of Abuse” by Agnieszka Sulima, Rashmi Jalah, Joshua F.G. Antoline, Oscar B Torres, Gregory H. Imler, Jeffrey R. Deschamps, Zoltan Beck, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice, and Gary R. Matyas in Journal of Medicinal Chemistry. Published online December 13 2017 doi:10.1021/acs.jmedchem.7b01427

Cite This NeuroscienceNews.com Article
U.S. Military HIV Research Program “New Vaccine Technology Shows Promise as a Tool to Combat the Opioid Crisis.” NeuroscienceNews. NeuroscienceNews, 18 December 2017.
<http://neurosciencenews.com/opioid-vaccine-8201/>.
U.S. Military HIV Research Program (2017, December 18). New Vaccine Technology Shows Promise as a Tool to Combat the Opioid Crisis. NeuroscienceNews. Retrieved December 18, 2017 from http://neurosciencenews.com/opioid-vaccine-8201/
U.S. Military HIV Research Program “New Vaccine Technology Shows Promise as a Tool to Combat the Opioid Crisis.” http://neurosciencenews.com/opioid-vaccine-8201/ (accessed December 18, 2017).

Abstract

A Stable Heroin Analog That Can Serve as a Vaccine Hapten to Induce Antibodies that Block the Effects of Heroin and its Metabolites in Rodents and that Cross-React Immunologically with Related Drugs of Abuse

An improved synthesis of a haptenic heroin surrogate 1 (6-AmHap) is reported. The intermediate needed for the preparation of 1 was described in the route in the synthesis of 2 (DiAmHap). A scalable procedure was developed to install the C-3 amido group. Using the Boc protectng group in 18 allowed preparation of 1 in an overall yield of 53% from 4 and eliminated the necessity of preparing the diamide 13. Hapten 1 was conjugated to tetanus toxoid and mixed with liposomes containing monophosphoryl lipid A as an adjuvant. The 1 vaccine induced high anti-1 IgG levels that reduced heroin-induced antinociception and locomotive behavioral changes following repeated subcutaneous and intravenous heroin challenges in mice and rats. Vaccinated mice had reduced heroin-induced hyperlocomotion following a 50 mg/kg heroin challenge. The 1 vaccine-induced antibodies bound to heroin and other abused opioids, including hydrocodone, oxycodone, hydromorphone, oxymorphone and codeine.

“A Stable Heroin Analog That Can Serve as a Vaccine Hapten to Induce Antibodies that Block the Effects of Heroin and its Metabolites in Rodents and that Cross-React Immunologically with Related Drugs of Abuse” by Agnieszka Sulima, Rashmi Jalah, Joshua F.G. Antoline, Oscar B Torres, Gregory H. Imler, Jeffrey R. Deschamps, Zoltan Beck, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice, and Gary R. Matyas in Journal of Medicinal Chemistry. Published online December 13 2017 doi:10.1021/acs.jmedchem.7b01427

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.
No more articles